Singapore markets closed

Roche Holding AG (RHHVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
329.00+15.86 (+5.06%)
As of 10:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close313.14
Open329.00
Bid0.00 x 0
Ask0.00 x 0
Day's range314.00 - 329.00
52-week range299.01 - 430.00
Volume6,089
Avg. volume6,761
Market cap259.469B
Beta (5Y monthly)0.28
PE ratio (TTM)18.01
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.97 (3.02%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Business Wire

    Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche

    SEATTLE, September 07, 2022--Good Therapeutics, a privately held company, today announced it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics.

  • Business Wire

    FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

    SOUTH SAN FRANCISCO, Calif., August 16, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA is e

  • Business Wire

    Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks the first single-dose oral influenza medicine